ReviewParasitology research2015
Research and control of advanced schistosomiasis japonica in China.
Review in Parasitology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Prevalence of depressive symptoms in patients with advanced schistosomiasis in China: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2024Pooled it
- Network Analysis and Nomogram in the Novel Classification and Prognosis Prediction of Advanced Schistosomiasis Japonica.The American journal of tropical medicine and hygiene · 2023Trial
- Field Testing Integrated Interventions for Schistosomiasis Elimination in the People's Republic of China: Outcomes of a Multifactorial Cluster-Randomized Controlled Trial.Frontiers in immunology · 2019Trial
- Article
- Prognostic determinants and mortality risk of advanced schistosomiasis revealed by Lasso-Cox regression integrative approach.PLoS neglected tropical diseases · 2026Article
- CXCR6 recruits Th2 cells and promotes liver fibrosis in schistosomiasis japonica.Hepatology communications · 2025Article
- Article
- Characteristics of Intestinal Flora in Patients With Schistosoma japonicum Infection Undergoing Splenectomy.Parasite immunology · 2025Article
- Dysregulated Glucuronidation of Bilirubin Exacerbates Liver Inflammation and Fibrosis in Schistosomiasis Japonica through the NF-κB Signaling Pathway.Pathogens (Basel, Switzerland) · 2024Article
- Alterations in gut microbiome and metabolite profile of patients with Schistosoma japonicum infection.Parasites & vectors · 2023Article
- The characteristics of intestinal microbiota in patients with chronic schistosomiasisFrontiers in microbiology · 2023Article
- Comparison of intestinal flora between patients with chronic and advanced Schistosoma japonicum infection.Parasites & vectors · 2022Article
- The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis.Journal of gastrointestinal oncology · 2022Article
- Potential Gut Microbiota Features for Non-Invasive Detection of Schistosomiasis.Frontiers in immunology · 2022Article
- Synergistic effect of combination chemotherapy with praziquantel and DW-3-15 for Schistosoma japonicum in vitro and in vivo.Parasites & vectors · 2021Article
- Higher frequency of circulating Vδ1 γδT cells in patients with advanced schistosomiasis.Parasite immunology · 2021Article
- The role of let-7b in the inhibition of hepatic stellate cell activation by rSjP40.PLoS neglected tropical diseases · 2021Article
- Gut microbiota signatures in Schistosoma japonicum infection-induced liver cirrhosis patients: a case-control study.Infectious diseases of poverty · 2021Article
- Human microRNAs in host-parasite interaction: a review.3 Biotech · 2020Review
- Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Schistosomiasis-Induced Liver Fibrosis.Cardiovascular and interventional radiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the three main schistosomes (Schistosoma japonicum, Schistosoma mansoni, and Schistosoma haematobium) known to infect humans, S. japonicum causes the most serious pathological lesions. In China, only schistosomiasis japonica is transmitted. From the 1950s, massive epidemiological investigations and active control measures for schistosomiasis japonica have been carried out. At the early stage of schistosomiasis control program, there were about 12 million schistosomiasis patients, and about 5% of schistosomiasis patients belong to advanced patients, which was 600,000. After more than a half century of active schistosomiasis control work, the schistosomiasis situation has been reduced markedly. The nearest epidemiological investigation showed that, by the end of 2012, there were still 240,000 schistosomiasis patients with the descent rate of 98% and 30,000 advanced patients with the descent rate of 95%. This paper reviews the rich experiences of advanced schistosomiasis research and control in China, including that the epidemiology researches confirm there is a family aggregation of advanced schistosomiasis and advanced schistosomiasis patients have no significance to the schistosomiasis transmission in transmission-interrupted areas but still are an infection source in endemic areas; pathogenic mechanism researches verify that genetic factors and immunoregulation play important roles in the disease developing process; ultrasound image examinations are used not only in the diagnosis and differential diagnosis of advanced schistosomiasis but also in the guidance of treatment and evaluation of therapeutic effects and, furthermore, in the risk predictions of portal hypertension and upper gastrointestinal hemorrhage; clinical practices demonstrate that praziquantel can be used in most of advanced schistosomiasis patients, and the therapy not only can interrupt the schistosomiasis transmission somewhat but also is favorable for liver fibrosis improvement; the ascetic fluid concentration afflux is used in the therapy for obstinate ascites, and endoscopic varices ligation is used in the treatment of upper gastrointestinal bleeding, and both have good effects; hundreds and thousands of severe splenomegaly advanced schistosomiasis patients received splenectomy, and the long-term survival rate is more than 90%, most of them are basically cured from the disease and their labor force recovers, some dwarf patients begin growing and developing again, and some sterile women became fertile; the researches of traditional Chinese medicine in the treatment of liver fibrosis have made progress, such as Cordyceps sinensis showing some anti-fibrosis effect in the animal experiments and primary clinical trials; the animal experiments and epidemiological investigations indicate that schistosome infection is one of the carcinogenesis risk factors, especially for liver cancer. In conclusion, these experiences and lessons are plentiful and worth sharing with the peers of other endemic countries for reference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.